###begin article-title 0
Analysis of R213R and 13494 g-->a polymorphisms of the p53 gene in individuals with esophagitis, intestinal metaplasia of the cardia and Barrett's Esophagus compared with a control group
###end article-title 0
###begin p 1
###xml 502 510 <span type="species:ncbi:9606">patients</span>
###xml 640 648 <span type="species:ncbi:9606">patients</span>
###xml 962 970 <span type="species:ncbi:9606">patients</span>
###xml 1033 1040 <span type="species:ncbi:9606">patient</span>
###xml 1142 1150 <span type="species:ncbi:9606">patients</span>
###xml 1422 1430 <span type="species:ncbi:9606">patients</span>
Protein p53 is the tumor suppressor involved in cell cycle control and apoptosis. There are several polymorphisms reported for p53 which can affect important regions involved in protein tumor suppressor activity. Amongst the polymorphisms described, R213R and 13949 g-->a are rarely studied, with an estimate frequency not yet available for the Brazilian population. The purpose of this study was to investigate the genotype and allele frequencies and associations of these polymorphisms in a group of patients with altered esophageal tissue from South Brazil and compare with the frequency observed for a control population. A total of 35 patients for R213R and 45 for 13494 g-->a polymorphisms analysis with gastroesophageal reflux disease (GERD) symptoms diagnosed by upper digestive endoscopy and confirmed by biopsy were studied. For both groups, 100 controls were used for comparison. Loss of heterozygosity (LOH) was also analyzed for a selected group of patients where normal and affected tissue was available. There was one patient with Barrett's Esophagus (BE) showing LOH for R213R out of two heterozygous samples analyzed and two patients (esophagitis and BE) for 13494 g-->a polymorphism. We also aimed to build a haplotype for both polymorphisms collectively analyzed with R27P polymorphism, previously reported by our group. There were no significant differences in allele and genotype distribution between patients and controls. Although using esophagitis, intestinal metaplasia of the cardia and BE samples, all non-neoplastic lesions, we can conclude that these sites do not represent genetic susceptibility markers for the development and early progression of GERD to BE and esophageal cancer. Additional studies are required in order to investigate other determiners of early premalignant lesions known to predispose to esophageal cancer.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 330 334 330 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">1996</xref>
###xml 207 215 <span type="species:ncbi:9606">patients</span>
Barrett's Esophagus (BE) is a complication of the gastroesophageal reflux disease being an acquired premalignant disorder that predisposes to the development of adenocarcinoma of the esophagus in 10% of the patients. It is also used as a model to investigate the order of genetic events in neoplastic progression (Audrezet et al. 1996).
###end p 4
###begin p 5
###xml 716 720 716 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">1990</xref>
The progressive evolution of the normal esophageal epithelium into the columnar-type epithelium in BE is characterized by a complex sequence of events beginning with inflammation of the normal squamous epithelium (esophagitis), resulting from chronic reflux, followed by intestinal metaplasia of the cardia (IMC) and BE, increasing levels of dysplasia, and adenocarcinoma. This process is modulated by environmental stimuli and genetic predisposition that result in genomic instability. Cells with multiple developed genetic abnormalities result in cellular clones with acquired genetic errors. Some clones acquire proliferative advantage and may develop capacity for invasion, resulting in neoplasia (Blount et al. 1990).
###end p 5
###begin p 6
###xml 230 234 230 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">1987</xref>
###xml 255 259 255 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">1989</xref>
###xml 273 277 273 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">1992</xref>
Several studies have focused on the metaplasia-adenocarcinoma transition while little is still known with respect to molecular factors that contribute to the development of alterations preceding intestinal metaplasia (Reid et al. 1987; Rabinovitch et al. 1989; Reid et al. 1992). The activity of several genes has been used to pinpoint alterations in the progression that leads to dysplasia and adenocarcinoma.
###end p 6
###begin p 7
###xml 15 19 15 19 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">1994</xref>
###xml 381 385 381 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">1994</xref>
###xml 398 402 398 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2005</xref>
Neshat et al. (1994) described the molecular alterations related to esophagus neoplasia. Gene mutations in the tumor-suppressing p53 gene were the abnormalities most commonly reported. The incidence of mutations tends to increase with the metaplasia-dysplasia-adenocarcinoma progression, ranging from rare in non-dysplastic epithelium to up to 90% in adenocarcinoma (Neshat et al. 1994; Fitzgerald 2005).
###end p 7
###begin p 8
###xml 266 270 266 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">1993</xref>
###xml 279 283 279 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">1996</xref>
More than 90% of the mutations described for the p53 gene occur between exons 4 and 9, which encompass protein domains II-V. This region is evolutionarily highly conserved and involves the DNA-binding domain, essential for the activity of p53 (Donehower and Bradley 1993; Soussi 1996).
###end p 8
###begin p 9
###xml 379 383 379 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2003</xref>
p53 gene mutations can damage its DNA-binding or transactivation functions, thereby inhibiting its key role in the cell cycle control. In the majority of these cases where the mutation is recessive, tumor cells often retained only the mutated allele and lose the wild type, while blood cells harbor both alleles. This loss is named loss of heterozygosity (LOH) (Baccouche et al. 2003).
###end p 9
###begin p 10
###xml 173 177 173 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">1999</xref>
Chromosomal regions with frequent LOH may point out those genes with higher susceptibility and help to understand the molecular events involved in carcinogenesis (Hu et al. 1999).
###end p 10
###begin p 11
###xml 211 215 211 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">1999</xref>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Mutations in tumor suppressor p53 gene have been detected in more than 25% of patients with Barrett's metaplasia submitted to endoscopy and in more than 75% of Barrett's adenocarcinomas (Aldulaimi and Jankowski 1999).
###end p 11
###begin p 12
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">2007</xref>
In addition to cancer-associated mutations, at least 200 polymorphisms have already been described at the p53 gene, both in coding and noncoding regions (IARC, NCI, NCBI, 2007), although most of them are located in introns outside the consensus region of splicing sites.
###end p 12
###begin p 13
###xml 155 159 155 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">2002</xref>
###xml 178 182 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">1991</xref>
###xml 201 205 201 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2003</xref>
Studies indicate that the preferential polymorphic alleles of the gene may be involved with susceptibility and predisposition to cancer. (Soulitzis et al. 2002; Olschwang et al. 1991; Baccouche et al. 2003).
###end p 13
###begin p 14
Among these, the polymorphism R213R in exon 6 and the polymorphism 13949 g-->a in intron 6 are rarely studied, with an estimate frequency not yet available for the Brazilian population (IARC). The R213R polymorphism retains the arginine amino acid, the most frequent codon being CGA and the polymorphic, CGG. The polymorphism 13494 g-->a shows adenine replacing guanine. No phenotypic differences were reported in both cases.
###end p 14
###begin p 15
###xml 741 745 739 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2006</xref>
###xml 436 444 <span type="species:ncbi:9606">patients</span>
Our study aimed to estimate the frequency of R213R and 13494 g-->a polymorphisms in control individuals, who represent the population of Porto Alegre, and in individuals with alterations in the esophageal tissue from the southernmost region of Brazil. In addition, we studied the potential association between the frequencies of this polymorphism in these two groups. The analysis of normal and altered tissue obtained from some of the patients allowed us to check for the existence of loss of heterozygosity in these regions of the gene. Furthermore, it also purports to build a haplotype for both polymorphisms collectively analyzed with the R27P polymorphism of exon 4 of the TP53, previously analyzed by our group (Leistner-Segal et al. 2006).
###end p 15
###begin title 16
Materials and methods 
###end title 16
###begin title 17
Study design
###end title 17
###begin p 18
###xml 120 128 <span type="species:ncbi:9606">patients</span>
###xml 238 246 <span type="species:ncbi:9606">patients</span>
This is a case control study designed to determine the relative frequency of three p53 polymorphisms in controls versus patients with GERD and complications such as BE. In addition, the study was designed to identify LOH at these loci in patients.
###end p 18
###begin title 19
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and controls
###end title 19
###begin p 20
###xml 502 506 500 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">2004</xref>
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 795 803 <span type="species:ncbi:9606">patients</span>
A total of 35 patients (17 female and 18 male; ages ranging between 23 years and 82 years; average of 51.1 years) with gastroesophageal reflux disease (GERD) symptoms diagnosed by upper digestive endoscopy and confirmed by biopsy were analyzed for the R213R polymorphism, while for the 13494 g-->a polymorphism analysis a total of 45 individuals (22 female and 23 male; ages ranging between 23  years and 82 years; average of 51.4 years) were used. The biopsies were analyzed according to Segal et al. 2004. For controls, 100 donor samples from Hospital de Clinicas of Porto Alegre Blood Bank were analyzed. This project was approved by the Ethic Committee of HCPA (03191) and National Committee for Ethics and Research (7945). All procedures were performed with written informed consent of the patients.
###end p 20
###begin title 21
DNA extraction
###end title 21
###begin p 22
###xml 166 170 166 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">1988</xref>
###xml 405 409 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2006</xref>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 255 263 <span type="species:ncbi:9606">patients</span>
Ten milliliters of peripheral blood in EDTA was withdrawn from controls and patients and DNA was isolated using the salting out procedure described by Miller et al. (1988). In addition, tissue from the lesion site was obtained by biopsy at endoscopy from patients showing esophageal alterations. DNA extraction from tissue was performed freshly, carried out as previously described (Leistner-Segal et al. 2006). Because we did not perform laser microdissection in the affected tissue, it is possible that these samples may also contain cells carrying normal DNA.
###end p 22
###begin title 23
Conditions for polymerase chain reaction (PCR)
###end title 23
###begin p 24
###xml 218 222 218 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">2004</xref>
###xml 445 446 424 425 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
The long PCR technique of exons 5 to 8 of the p53 gene was set as standard. Hence, exon 5 forward (5'CTGCCCTGACTTTCAACTCTG3') and exon 8 reverse (5'TGCACCCTTGGTCTCCTCCAC3') primers were used, according to Segal et al. 2004 (31). Amplifications were carried out using approximately 200 ng DNA, 1 U Taq DNA Polymerase (Invitrogentrade mark), 5 mul enzyme buffer (Tris-HCl 200 mM, KCl 500 mM), 5 mul dNTP 0.2 mM (Invitrogentrade mark), 1.5 mul MgCl2 (50 mM), and 1.0 mul of each specific primer at a concentration of 20 pmol for a final reaction volume of 50 mul.
###end p 24
###begin p 25
PCR conditions were: initial denaturation at 94degreesC for 3 min., followed by 35 cycles of 40 s, with 94degreesC of denaturation, 55degreesC of annealing and extension at 72degreesC, and final extension of 72degreesC for 10 min. The amplified fragment of 1619 pb was submitted to 1.5% agarose gel electrophoresis and visualized through ethidium bromide staining.
###end p 25
###begin title 26
Digestion with restriction enzymes 
###end title 26
###begin p 27
###xml 0 27 0 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R213R (exon 6) polymorphism</italic>
###xml 121 124 121 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 475 478 458 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
R213R (exon 6) polymorphism: to identify the R213R polymorphism, digestion of the long PCR product was carried out using TaqI (New England BioLabstrade mark) enzyme to cleave the T'CGA site, according to the manufacturer's instructions. The digestion used 10 mul of the PCR product and 2 U of the enzyme in a total final volume of 30 mul. The reaction was kept at 65degreesC in a thermocycler for 2 h and 30 min. Fragments resulting from cleavage of the PCR product with the TaqI enzyme are 385, 309 and 925 bp in the presence of the CGA sequence, and 694 and 925 bp in the presence of the CGG sequence.
###end p 27
###begin p 28
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">13494 g</italic>
###xml 10 35 8 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a (intron 6) polymorphism</italic>
###xml 139 142 135 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
###xml 473 476 452 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
13494 g-->a (intron 6) polymorphism: to identify the 13494 g-->a polymorphism, digestion on the long PCR product was carried out using the MspI (New England BioLabstrade mark) enzyme to cleave the C'CGG site, according to the manufacturer's instructions. The digestion used 10 mul of the PCR product and 2 U of the enzyme in a total final volume of 30 mul. The reaction was incubated at 37degreesC in dry bath. Fragments resulting from cleavage of the PCR product with the MspI enzyme are 124, 356, 276, 299, 168, 276 and 120 bp in the presence of the CGG sequence, and 124, 632, 299, 168, 276 and 120 bp in the presence of the CAG sequence.
###end p 28
###begin p 29
###xml 120 121 120 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 123 129 123 129 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 205 208 205 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 214 217 214 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
###xml 129 526 129 524 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Agarose gel (3.0%) showing long PCR results and digestions carried out with <italic>Taq</italic>I and <italic>Msp</italic>I. Position 8 shows the 100&#160;bp molecular weight marker. Position 1 shows the long PCR product concerning exons 5 to 8 in the TP53. Positions 2, 3 and 4 show the allelic patterns AA and AG for the R213R polymorphism. Positions 5, 6 and 7 show the allelic patterns AA, AG and GG for the 13494 g&#8594;a polymorphism</p>
###xml 129 526 129 524 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">Agarose gel (3.0%) showing long PCR results and digestions carried out with <italic>Taq</italic>I and <italic>Msp</italic>I. Position 8 shows the 100&#160;bp molecular weight marker. Position 1 shows the long PCR product concerning exons 5 to 8 in the TP53. Positions 2, 3 and 4 show the allelic patterns AA and AG for the R213R polymorphism. Positions 5, 6 and 7 show the allelic patterns AA, AG and GG for the 13494 g&#8594;a polymorphism</p></caption>
###xml 526 526 524 524 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="11568_2007_9007_Fig1_HTML" id="MO1"/>
###xml 123 526 123 524 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="30">Agarose gel (3.0%) showing long PCR results and digestions carried out with <italic>Taq</italic>I and <italic>Msp</italic>I. Position 8 shows the 100&#160;bp molecular weight marker. Position 1 shows the long PCR product concerning exons 5 to 8 in the TP53. Positions 2, 3 and 4 show the allelic patterns AA and AG for the R213R polymorphism. Positions 5, 6 and 7 show the allelic patterns AA, AG and GG for the 13494 g&#8594;a polymorphism</p></caption><graphic position="anchor" xlink:href="11568_2007_9007_Fig1_HTML" id="MO1"/></fig>
Both digestion products were subject to electrophoresis in 3% agarose gel. The band pattern found is visualized in Fig. 1. Fig. 1Agarose gel (3.0%) showing long PCR results and digestions carried out with TaqI and MspI. Position 8 shows the 100 bp molecular weight marker. Position 1 shows the long PCR product concerning exons 5 to 8 in the TP53. Positions 2, 3 and 4 show the allelic patterns AA and AG for the R213R polymorphism. Positions 5, 6 and 7 show the allelic patterns AA, AG and GG for the 13494 g-->a polymorphism
###end p 29
###begin p 30
###xml 76 79 76 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 85 88 85 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
Agarose gel (3.0%) showing long PCR results and digestions carried out with TaqI and MspI. Position 8 shows the 100 bp molecular weight marker. Position 1 shows the long PCR product concerning exons 5 to 8 in the TP53. Positions 2, 3 and 4 show the allelic patterns AA and AG for the R213R polymorphism. Positions 5, 6 and 7 show the allelic patterns AA, AG and GG for the 13494 g-->a polymorphism
###end p 30
###begin p 31
The statistical analysis of results was performed using a Pearson's chi-square test in the MedCalctrade mark software.
###end p 31
###begin title 32
Loss of heterozygosity analysis
###end title 32
###begin p 33
###xml 185 186 185 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 222 223 222 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 77 84 <span type="species:ncbi:9606">patient</span>
For this study, the DNA extracted from blood and affected tissue of the same patient was analyzed. Only individuals who presented a heterozygous pattern in their blood were considered (n = 2 for the R213R polymorphism and n = 12 for the 13494 g-->a polymorphism), respectively 8% and 33% of the sample for each polymorphism.
###end p 33
###begin title 34
Results
###end title 34
###begin title 35
Clinical signs
###end title 35
###begin p 36
###xml 4 12 <span type="species:ncbi:9606">patients</span>
All patients showed signs of GERD. For R213R polymorphism analysis, 20% (7/35) showed esophagitis, 37.1% (13/45) showed IMC and 42.9% (15/35) showed BE. For the 13494 g-->a polymorphism, 27% (12/45) showed esophagitis, 37.8% (17/45) IMC and 35.6% (16/45) BE.
###end p 36
###begin title 37
Long PCR technique standardization
###end title 37
###begin p 38
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
The presented methodology proved to be adequate for amplification of a relatively long segment involving four significant exons for the p53 protein function, as shown in Fig. 1.
###end p 38
###begin title 39
Identification of R213R (exon 6) polymorphism
###end title 39
###begin p 40
###xml 280 281 280 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 431 432 431 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 445 446 445 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 471 478 471 478 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 478 558 478 558 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="41">Genotype and allele frequency of the R213R polymorphism in patients and controls</p>
###xml 478 558 478 558 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="41">Genotype and allele frequency of the R213R polymorphism in patients and controls</p></caption>
###xml 558 563 558 563 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Group</th>
###xml 563 571 563 571 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">Genotype</th>
###xml 571 577 571 577 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Allele</th>
###xml 558 577 558 577 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2">Group</th><th align="left" colspan="3">Genotype</th><th align="left" colspan="2">Allele</th></tr>
###xml 577 579 577 579 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</th>
###xml 579 581 579 581 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AG</th>
###xml 581 583 581 583 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</th>
###xml 583 584 583 584 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">A</th>
###xml 584 585 584 585 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G</th>
###xml 577 585 577 585 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">AA</th><th align="left">AG</th><th align="left">GG</th><th align="left">A</th><th align="left">G</th></tr>
###xml 558 585 558 585 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="2">Group</th><th align="left" colspan="3">Genotype</th><th align="left" colspan="2">Allele</th></tr><tr><th align="left">AA</th><th align="left">AG</th><th align="left">GG</th><th align="left">A</th><th align="left">G</th></tr></thead>
###xml 595 596 595 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 585 603 585 603 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Controls (<italic>n</italic>&#160;=&#160;100)</td>
###xml 603 613 603 613 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">96 (0.960)</td>
###xml 613 622 613 622 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4 (0.040)</td>
###xml 622 630 622 630 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0 (0.00)</td>
###xml 630 641 630 641 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">196 (0.980)</td>
###xml 641 649 641 649 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4 (0.02)</td>
###xml 585 649 585 649 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Controls (<italic>n</italic>&#160;=&#160;100)</td><td align="left">96 (0.960)</td><td align="left">4 (0.040)</td><td align="left">0 (0.00)</td><td align="left">196 (0.980)</td><td align="left">4 (0.02)</td></tr>
###xml 659 660 659 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 649 666 649 666 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Patients (<italic>n</italic>&#160;=&#160;35)</td>
###xml 666 676 666 676 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">33 (0.943)</td>
###xml 676 685 676 685 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2 (0.057)</td>
###xml 685 693 685 693 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0 (0.00)</td>
###xml 693 703 693 703 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">68 (0.971)</td>
###xml 703 712 703 712 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2 (0.028)</td>
###xml 649 712 649 712 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Patients (<italic>n</italic>&#160;=&#160;35)</td><td align="left">33 (0.943)</td><td align="left">2 (0.057)</td><td align="left">0 (0.00)</td><td align="left">68 (0.971)</td><td align="left">2 (0.028)</td></tr>
###xml 585 712 585 712 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Controls (<italic>n</italic>&#160;=&#160;100)</td><td align="left">96 (0.960)</td><td align="left">4 (0.040)</td><td align="left">0 (0.00)</td><td align="left">196 (0.980)</td><td align="left">4 (0.02)</td></tr><tr><td align="left">Patients (<italic>n</italic>&#160;=&#160;35)</td><td align="left">33 (0.943)</td><td align="left">2 (0.057)</td><td align="left">0 (0.00)</td><td align="left">68 (0.971)</td><td align="left">2 (0.028)</td></tr></tbody>
###xml 558 712 558 712 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Group</th><th align="left" colspan="3">Genotype</th><th align="left" colspan="2">Allele</th></tr><tr><th align="left">AA</th><th align="left">AG</th><th align="left">GG</th><th align="left">A</th><th align="left">G</th></tr></thead><tbody><tr><td align="left">Controls (<italic>n</italic>&#160;=&#160;100)</td><td align="left">96 (0.960)</td><td align="left">4 (0.040)</td><td align="left">0 (0.00)</td><td align="left">196 (0.980)</td><td align="left">4 (0.02)</td></tr><tr><td align="left">Patients (<italic>n</italic>&#160;=&#160;35)</td><td align="left">33 (0.943)</td><td align="left">2 (0.057)</td><td align="left">0 (0.00)</td><td align="left">68 (0.971)</td><td align="left">2 (0.028)</td></tr></tbody></table>
###xml 471 712 471 712 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="41">Genotype and allele frequency of the R213R polymorphism in patients and controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Group</th><th align="left" colspan="3">Genotype</th><th align="left" colspan="2">Allele</th></tr><tr><th align="left">AA</th><th align="left">AG</th><th align="left">GG</th><th align="left">A</th><th align="left">G</th></tr></thead><tbody><tr><td align="left">Controls (<italic>n</italic>&#160;=&#160;100)</td><td align="left">96 (0.960)</td><td align="left">4 (0.040)</td><td align="left">0 (0.00)</td><td align="left">196 (0.980)</td><td align="left">4 (0.02)</td></tr><tr><td align="left">Patients (<italic>n</italic>&#160;=&#160;35)</td><td align="left">33 (0.943)</td><td align="left">2 (0.057)</td><td align="left">0 (0.00)</td><td align="left">68 (0.971)</td><td align="left">2 (0.028)</td></tr></tbody></table></table-wrap>
###xml 18 26 <span type="species:ncbi:9606">patients</span>
###xml 216 224 <span type="species:ncbi:9606">patients</span>
###xml 537 545 <span type="species:ncbi:9606">patients</span>
###xml 649 657 <span type="species:ncbi:9606">Patients</span>
In both groups of patients and controls a predominance of the allele (A) was noticed, with no homozygosis for the polymorphic allele (G) being reported. This was only found in heterozygosis in two individuals in the patients group and four in the control group, as shown on Table 1. The frequencies found for this polymorphism were notably similar in both groups, without significant difference for genotypic and allelic analysis (P = 0.958 and P = 0.957, respectively). Table 1Genotype and allele frequency of the R213R polymorphism in patients and controlsGroupGenotypeAlleleAAAGGGAGControls (n = 100)96 (0.960)4 (0.040)0 (0.00)196 (0.980)4 (0.02)Patients (n = 35)33 (0.943)2 (0.057)0 (0.00)68 (0.971)2 (0.028)
###end p 40
###begin p 41
###xml 59 67 <span type="species:ncbi:9606">patients</span>
Genotype and allele frequency of the R213R polymorphism in patients and controls
###end p 41
###begin p 42
###xml 8 16 <span type="species:ncbi:9606">patients</span>
The two patients presenting the allele (G) in heterozygosis showed IMC and BE.
###end p 42
###begin p 43
###xml 137 138 137 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 161 165 161 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1999</xref>
###xml 353 354 353 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 364 365 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 375 376 375 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 389 390 389 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
These results were compared with literature data and no significant difference was observed among frequencies of the polymorphic allele (P = 0.978) (Akar et al. 1999). When comparing with an American population, no significant difference was found, not even in comparison with Afro-American, Caucasian and Hispanic subpopulations within the same study (P = 0.913, P = 0.726, P = 0.736 and P = 0.687, respectively) (NCI).
###end p 43
###begin p 44
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 30 33 30 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
Figure 1 shows the results of TaqI digestion, highlighting the possible alleles.
###end p 44
###begin title 45
Identification of the 13494 g-->a (intron 6) polymorphism
###end title 45
###begin p 46
###xml 231 232 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 461 462 459 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 475 476 473 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 501 508 499 506 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 508 593 506 589 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="47">Genotype and allele frequency of the 13494g&#8594;a polymorphism in patients and controls</p>
###xml 508 593 506 589 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="47">Genotype and allele frequency of the 13494g&#8594;a polymorphism in patients and controls</p></caption>
###xml 593 598 589 594 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Group</th>
###xml 598 606 594 602 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">Genotype</th>
###xml 606 612 602 608 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Allele</th>
###xml 593 612 589 608 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2">Group</th><th align="left" colspan="3">Genotype</th><th align="left" colspan="2">Allele</th></tr>
###xml 612 614 608 610 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</th>
###xml 614 616 610 612 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AG</th>
###xml 616 618 612 614 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</th>
###xml 618 619 614 615 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">A</th>
###xml 619 620 615 616 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">G</th>
###xml 612 620 608 616 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">AA</th><th align="left">AG</th><th align="left">GG</th><th align="left">A</th><th align="left">G</th></tr>
###xml 593 620 589 616 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="2">Group</th><th align="left" colspan="3">Genotype</th><th align="left" colspan="2">Allele</th></tr><tr><th align="left">AA</th><th align="left">AG</th><th align="left">GG</th><th align="left">A</th><th align="left">G</th></tr></thead>
###xml 630 631 626 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 620 638 616 634 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Controls (<italic>n</italic>&#160;=&#160;100)</td>
###xml 638 647 634 643 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4 (0.040)</td>
###xml 647 657 643 653 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">25 (0.250)</td>
###xml 657 667 653 663 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">71 (0.710)</td>
###xml 667 677 663 673 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">33 (0.165)</td>
###xml 677 688 673 684 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">167 (0.835)</td>
###xml 620 688 616 684 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Controls (<italic>n</italic>&#160;=&#160;100)</td><td align="left">4 (0.040)</td><td align="left">25 (0.250)</td><td align="left">71 (0.710)</td><td align="left">33 (0.165)</td><td align="left">167 (0.835)</td></tr>
###xml 698 699 694 695 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 688 705 684 701 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Patients (<italic>n</italic>&#160;=&#160;45)</td>
###xml 705 714 701 710 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">0 (0.000)</td>
###xml 714 724 710 720 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">12 (0.267)</td>
###xml 724 734 720 730 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">33 (0.733)</td>
###xml 734 744 730 740 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">12 (0.133)</td>
###xml 744 754 740 750 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">78 (0.867)</td>
###xml 688 754 684 750 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Patients (<italic>n</italic>&#160;=&#160;45)</td><td align="left">0 (0.000)</td><td align="left">12 (0.267)</td><td align="left">33 (0.733)</td><td align="left">12 (0.133)</td><td align="left">78 (0.867)</td></tr>
###xml 620 754 616 750 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Controls (<italic>n</italic>&#160;=&#160;100)</td><td align="left">4 (0.040)</td><td align="left">25 (0.250)</td><td align="left">71 (0.710)</td><td align="left">33 (0.165)</td><td align="left">167 (0.835)</td></tr><tr><td align="left">Patients (<italic>n</italic>&#160;=&#160;45)</td><td align="left">0 (0.000)</td><td align="left">12 (0.267)</td><td align="left">33 (0.733)</td><td align="left">12 (0.133)</td><td align="left">78 (0.867)</td></tr></tbody>
###xml 593 754 589 750 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Group</th><th align="left" colspan="3">Genotype</th><th align="left" colspan="2">Allele</th></tr><tr><th align="left">AA</th><th align="left">AG</th><th align="left">GG</th><th align="left">A</th><th align="left">G</th></tr></thead><tbody><tr><td align="left">Controls (<italic>n</italic>&#160;=&#160;100)</td><td align="left">4 (0.040)</td><td align="left">25 (0.250)</td><td align="left">71 (0.710)</td><td align="left">33 (0.165)</td><td align="left">167 (0.835)</td></tr><tr><td align="left">Patients (<italic>n</italic>&#160;=&#160;45)</td><td align="left">0 (0.000)</td><td align="left">12 (0.267)</td><td align="left">33 (0.733)</td><td align="left">12 (0.133)</td><td align="left">78 (0.867)</td></tr></tbody></table>
###xml 501 754 499 750 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="47">Genotype and allele frequency of the 13494g&#8594;a polymorphism in patients and controls</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Group</th><th align="left" colspan="3">Genotype</th><th align="left" colspan="2">Allele</th></tr><tr><th align="left">AA</th><th align="left">AG</th><th align="left">GG</th><th align="left">A</th><th align="left">G</th></tr></thead><tbody><tr><td align="left">Controls (<italic>n</italic>&#160;=&#160;100)</td><td align="left">4 (0.040)</td><td align="left">25 (0.250)</td><td align="left">71 (0.710)</td><td align="left">33 (0.165)</td><td align="left">167 (0.835)</td></tr><tr><td align="left">Patients (<italic>n</italic>&#160;=&#160;45)</td><td align="left">0 (0.000)</td><td align="left">12 (0.267)</td><td align="left">33 (0.733)</td><td align="left">12 (0.133)</td><td align="left">78 (0.867)</td></tr></tbody></table></table-wrap>
###xml 18 26 <span type="species:ncbi:9606">patients</span>
###xml 198 205 <span type="species:ncbi:9606">patient</span>
###xml 384 392 <span type="species:ncbi:9606">patients</span>
###xml 572 580 <span type="species:ncbi:9606">patients</span>
###xml 688 696 <span type="species:ncbi:9606">Patients</span>
In both groups of patients and controls predominance of the allele (G) was observed, with homozygosis found for the polymorphic allele (A) in four individuals from the control group and none in the patient group, as shown in Table 2. Similar to the R213R polymorphism, the frequency analysis of the 13494 g-->a polymorphism did not present a significant difference when comparing the patients with the control group for both the genotypic and allelic analysis (P = 0.607 and P = 0.395, respectively). Table 2Genotype and allele frequency of the 13494g-->a polymorphism in patients and controlsGroupGenotypeAlleleAAAGGGAGControls (n = 100)4 (0.040)25 (0.250)71 (0.710)33 (0.165)167 (0.835)Patients (n = 45)0 (0.000)12 (0.267)33 (0.733)12 (0.133)78 (0.867)
###end p 46
###begin p 47
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Genotype and allele frequency of the 13494g-->a polymorphism in patients and controls
###end p 47
###begin p 48
###xml 4 12 <span type="species:ncbi:9606">patients</span>
The patients that present the polymorphic allele (A) showed esophagitis (4/45), IMC (5/45) and BE (3/45).
###end p 48
###begin p 49
###xml 168 172 168 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1999</xref>
###xml 292 293 292 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
When the frequencies found in our population were superimposed over the literature data, a significant difference was noted. The population analyzed in the Akar et al. 1999 study showed a frequency of 0.3 polymorphic alleles, thus differing from the findings in this study, which were 0.165 (P = 0.008).
###end p 49
###begin p 50
###xml 198 199 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 209 210 209 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 220 221 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 234 235 234 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 282 286 282 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">2002</xref>
When comparing to an American population, no significant difference was found, not even in comparison with Afro-American, Caucasian, Hispanic and Pacific Coast subpopulations within the same study (P = 0.928, P = 0.404, P = 0.467 and P = 0.723, respectively) (Shaheen and Ransohoff 2002).
###end p 50
###begin p 51
###xml 7 8 7 8 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 29 32 29 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Msp</italic>
Figure 1 shows the result of MspI digestion, highlighting the possible alleles.
###end p 51
###begin title 52
Loss of heterozygosity
###end title 52
###begin p 53
###xml 74 81 <span type="species:ncbi:9606">patient</span>
The analysis consisted in pairs of blood and tissue samples from the same patient.
###end p 53
###begin p 54
###xml 106 113 <span type="species:ncbi:9606">patient</span>
###xml 186 194 <span type="species:ncbi:9606">patients</span>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
One case of LOH (4.0%), out of two heterozygous samples analyzed, was found for the R213R polymorphism, a patient carrying BE. For the 13494 g-->a polymorphism, LOH was confirmed in two patients (7.4%), a carrier of esophagitis and another one BE. The polymorphic allele present in the peripheral blood sample was not kept in the tissues of these two patients, confirming the stress in such tissues even when the wild allele was preserved.
###end p 54
###begin title 55
Haplotype analysis for the R213R, 13494 g-->a and R72P polymorphisms
###end title 55
###begin p 56
###xml 172 176 170 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2006</xref>
###xml 306 307 304 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 309 316 307 314 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 316 394 314 390 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="57">Haplotype analysis involving R213R, 13494 g&#8594;a and R72P polymorphisms of TP53</p>
###xml 316 394 314 390 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="57">Haplotype analysis involving R213R, 13494 g&#8594;a and R72P polymorphisms of TP53</p></caption>
###xml 394 401 390 397 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Patient</th>
###xml 401 406 397 402 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">R213R</th>
###xml 406 417 402 411 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">13494 g&#8594;a</th>
###xml 417 421 411 415 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">R72P</th>
###xml 421 438 415 432 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Histological type</th>
###xml 394 438 390 432 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Patient</th><th align="left">R213R</th><th align="left">13494 g&#8594;a</th><th align="left">R72P</th><th align="left">Histological type</th></tr>
###xml 394 438 390 432 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Patient</th><th align="left">R213R</th><th align="left">13494 g&#8594;a</th><th align="left">R72P</th><th align="left">Histological type</th></tr></thead>
###xml 438 444 432 438 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 1</td>
###xml 444 446 438 440 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 446 448 440 442 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 448 450 442 444 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PR</td>
###xml 450 452 444 446 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BE</td>
###xml 438 452 432 446 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 1</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr>
###xml 452 458 446 452 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 2</td>
###xml 458 460 452 454 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 460 462 454 456 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AG</td>
###xml 462 464 456 458 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RR</td>
###xml 464 466 458 460 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BE</td>
###xml 452 466 446 460 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 2</td><td align="left">AA</td><td align="left">AG</td><td align="left">RR</td><td align="left">BE</td></tr>
###xml 466 472 460 466 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 3</td>
###xml 472 474 466 468 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 474 476 468 470 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AG</td>
###xml 476 478 470 472 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RR</td>
###xml 478 480 472 474 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BE</td>
###xml 466 480 460 474 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 3</td><td align="left">AA</td><td align="left">AG</td><td align="left">RR</td><td align="left">BE</td></tr>
###xml 480 486 474 480 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 4</td>
###xml 486 488 480 482 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 488 490 482 484 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 490 492 484 486 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PR</td>
###xml 492 494 486 488 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BE</td>
###xml 480 494 474 488 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 4</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr>
###xml 494 500 488 494 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 5</td>
###xml 500 502 494 496 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 502 504 496 498 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AG</td>
###xml 504 506 498 500 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PR</td>
###xml 506 509 500 503 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IMC</td>
###xml 494 509 488 503 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 5</td><td align="left">AA</td><td align="left">AG</td><td align="left">PR</td><td align="left">IMC</td></tr>
###xml 509 515 503 509 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 6</td>
###xml 515 517 509 511 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 517 519 511 513 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 519 521 513 515 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PR</td>
###xml 521 532 515 526 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ESOPHAGITIS</td>
###xml 509 532 503 526 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 6</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">ESOPHAGITIS</td></tr>
###xml 532 538 526 532 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 7</td>
###xml 538 540 532 534 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 540 542 534 536 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AG</td>
###xml 542 544 536 538 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RR</td>
###xml 544 555 538 549 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ESOPHAGITIS</td>
###xml 532 555 526 549 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 7</td><td align="left">AA</td><td align="left">AG</td><td align="left">RR</td><td align="left">ESOPHAGITIS</td></tr>
###xml 555 561 549 555 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 8</td>
###xml 561 563 555 557 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 563 565 557 559 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 565 567 559 561 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RR</td>
###xml 567 570 561 564 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IMC</td>
###xml 555 570 549 564 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 8</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr>
###xml 570 576 564 570 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 9</td>
###xml 576 578 570 572 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 578 580 572 574 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 580 582 574 576 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RR</td>
###xml 582 584 576 578 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BE</td>
###xml 570 584 564 578 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 9</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">BE</td></tr>
###xml 584 591 578 585 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 10</td>
###xml 591 593 585 587 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 593 595 587 589 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 595 597 589 591 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RR</td>
###xml 597 600 591 594 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IMC</td>
###xml 584 600 578 594 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 10</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr>
###xml 600 607 594 601 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 11</td>
###xml 607 609 601 603 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 609 611 603 605 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 611 613 605 607 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PR</td>
###xml 613 615 607 609 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BE</td>
###xml 600 615 594 609 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 11</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr>
###xml 615 622 609 616 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 12</td>
###xml 622 624 616 618 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 624 626 618 620 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 626 628 620 622 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PR</td>
###xml 628 630 622 624 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BE</td>
###xml 615 630 609 624 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 12</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr>
###xml 630 637 624 631 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 13</td>
###xml 637 639 631 633 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 639 641 633 635 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AG</td>
###xml 641 643 635 637 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PR</td>
###xml 643 646 637 640 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IMC</td>
###xml 630 646 624 640 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 13</td><td align="left">AA</td><td align="left">AG</td><td align="left">PR</td><td align="left">IMC</td></tr>
###xml 646 653 640 647 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 14</td>
###xml 653 655 647 649 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 655 657 649 651 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 657 659 651 653 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RR</td>
###xml 659 670 653 664 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ESOPHAGITIS</td>
###xml 646 670 640 664 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 14</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">ESOPHAGITIS</td></tr>
###xml 670 677 664 671 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 15</td>
###xml 677 679 671 673 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 679 681 673 675 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AG</td>
###xml 681 683 675 677 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PR</td>
###xml 683 686 677 680 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IMC</td>
###xml 670 686 664 680 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 15</td><td align="left">AA</td><td align="left">AG</td><td align="left">PR</td><td align="left">IMC</td></tr>
###xml 686 693 680 687 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 16</td>
###xml 693 695 687 689 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 695 697 689 691 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 697 699 691 693 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RR</td>
###xml 699 702 693 696 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IMC</td>
###xml 686 702 680 696 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 16</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr>
###xml 702 709 696 703 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 17</td>
###xml 709 711 703 705 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AG</td>
###xml 711 713 705 707 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AG</td>
###xml 713 715 707 709 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PR</td>
###xml 715 717 709 711 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BE</td>
###xml 702 717 696 711 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 17</td><td align="left">AG</td><td align="left">AG</td><td align="left">PR</td><td align="left">BE</td></tr>
###xml 717 724 711 718 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 18</td>
###xml 724 726 718 720 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 726 728 720 722 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 728 730 722 724 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RR</td>
###xml 730 732 724 726 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BE</td>
###xml 717 732 711 726 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 18</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">BE</td></tr>
###xml 732 739 726 733 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 19</td>
###xml 739 741 733 735 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AG</td>
###xml 741 743 735 737 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 743 745 737 739 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RR</td>
###xml 745 748 739 742 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IMC</td>
###xml 732 748 726 742 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 19</td><td align="left">AG</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr>
###xml 748 755 742 749 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 20</td>
###xml 755 757 749 751 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 757 759 751 753 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AG</td>
###xml 759 761 753 755 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PP</td>
###xml 761 772 755 766 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ESOPHAGITIS</td>
###xml 748 772 742 766 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 20</td><td align="left">AA</td><td align="left">AG</td><td align="left">PP</td><td align="left">ESOPHAGITIS</td></tr>
###xml 772 779 766 773 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 21</td>
###xml 779 781 773 775 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 781 783 775 777 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 783 785 777 779 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RR</td>
###xml 785 796 779 790 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ESOPHAGITIS</td>
###xml 772 796 766 790 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 21</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">ESOPHAGITIS</td></tr>
###xml 796 803 790 797 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 22</td>
###xml 803 805 797 799 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 805 807 799 801 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 807 809 801 803 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RR</td>
###xml 809 812 803 806 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IMC</td>
###xml 796 812 790 806 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 22</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr>
###xml 812 819 806 813 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 23</td>
###xml 819 821 813 815 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 821 823 815 817 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 823 825 817 819 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">RR</td>
###xml 825 827 819 821 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BE</td>
###xml 812 827 806 821 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 23</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">BE</td></tr>
###xml 827 834 821 828 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 24</td>
###xml 834 836 828 830 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 836 838 830 832 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 838 840 832 834 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PR</td>
###xml 840 842 834 836 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BE</td>
###xml 827 842 821 836 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 24</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr>
###xml 842 849 836 843 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 25</td>
###xml 849 851 843 845 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 851 853 845 847 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 853 855 847 849 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PR</td>
###xml 855 858 849 852 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">IMC</td>
###xml 842 858 836 852 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 25</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">IMC</td></tr>
###xml 858 865 852 859 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case 26</td>
###xml 865 867 859 861 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AA</td>
###xml 867 869 861 863 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GG</td>
###xml 869 871 863 865 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PR</td>
###xml 871 873 865 867 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">BE</td>
###xml 858 873 852 867 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Case 26</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr>
###xml 438 873 432 867 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Case 1</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr><tr><td align="left">Case 2</td><td align="left">AA</td><td align="left">AG</td><td align="left">RR</td><td align="left">BE</td></tr><tr><td align="left">Case 3</td><td align="left">AA</td><td align="left">AG</td><td align="left">RR</td><td align="left">BE</td></tr><tr><td align="left">Case 4</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr><tr><td align="left">Case 5</td><td align="left">AA</td><td align="left">AG</td><td align="left">PR</td><td align="left">IMC</td></tr><tr><td align="left">Case 6</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">ESOPHAGITIS</td></tr><tr><td align="left">Case 7</td><td align="left">AA</td><td align="left">AG</td><td align="left">RR</td><td align="left">ESOPHAGITIS</td></tr><tr><td align="left">Case 8</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr><tr><td align="left">Case 9</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">BE</td></tr><tr><td align="left">Case 10</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr><tr><td align="left">Case 11</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr><tr><td align="left">Case 12</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr><tr><td align="left">Case 13</td><td align="left">AA</td><td align="left">AG</td><td align="left">PR</td><td align="left">IMC</td></tr><tr><td align="left">Case 14</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">ESOPHAGITIS</td></tr><tr><td align="left">Case 15</td><td align="left">AA</td><td align="left">AG</td><td align="left">PR</td><td align="left">IMC</td></tr><tr><td align="left">Case 16</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr><tr><td align="left">Case 17</td><td align="left">AG</td><td align="left">AG</td><td align="left">PR</td><td align="left">BE</td></tr><tr><td align="left">Case 18</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">BE</td></tr><tr><td align="left">Case 19</td><td align="left">AG</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr><tr><td align="left">Case 20</td><td align="left">AA</td><td align="left">AG</td><td align="left">PP</td><td align="left">ESOPHAGITIS</td></tr><tr><td align="left">Case 21</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">ESOPHAGITIS</td></tr><tr><td align="left">Case 22</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr><tr><td align="left">Case 23</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">BE</td></tr><tr><td align="left">Case 24</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr><tr><td align="left">Case 25</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">IMC</td></tr><tr><td align="left">Case 26</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr></tbody>
###xml 394 873 390 867 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Patient</th><th align="left">R213R</th><th align="left">13494 g&#8594;a</th><th align="left">R72P</th><th align="left">Histological type</th></tr></thead><tbody><tr><td align="left">Case 1</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr><tr><td align="left">Case 2</td><td align="left">AA</td><td align="left">AG</td><td align="left">RR</td><td align="left">BE</td></tr><tr><td align="left">Case 3</td><td align="left">AA</td><td align="left">AG</td><td align="left">RR</td><td align="left">BE</td></tr><tr><td align="left">Case 4</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr><tr><td align="left">Case 5</td><td align="left">AA</td><td align="left">AG</td><td align="left">PR</td><td align="left">IMC</td></tr><tr><td align="left">Case 6</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">ESOPHAGITIS</td></tr><tr><td align="left">Case 7</td><td align="left">AA</td><td align="left">AG</td><td align="left">RR</td><td align="left">ESOPHAGITIS</td></tr><tr><td align="left">Case 8</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr><tr><td align="left">Case 9</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">BE</td></tr><tr><td align="left">Case 10</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr><tr><td align="left">Case 11</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr><tr><td align="left">Case 12</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr><tr><td align="left">Case 13</td><td align="left">AA</td><td align="left">AG</td><td align="left">PR</td><td align="left">IMC</td></tr><tr><td align="left">Case 14</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">ESOPHAGITIS</td></tr><tr><td align="left">Case 15</td><td align="left">AA</td><td align="left">AG</td><td align="left">PR</td><td align="left">IMC</td></tr><tr><td align="left">Case 16</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr><tr><td align="left">Case 17</td><td align="left">AG</td><td align="left">AG</td><td align="left">PR</td><td align="left">BE</td></tr><tr><td align="left">Case 18</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">BE</td></tr><tr><td align="left">Case 19</td><td align="left">AG</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr><tr><td align="left">Case 20</td><td align="left">AA</td><td align="left">AG</td><td align="left">PP</td><td align="left">ESOPHAGITIS</td></tr><tr><td align="left">Case 21</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">ESOPHAGITIS</td></tr><tr><td align="left">Case 22</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr><tr><td align="left">Case 23</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">BE</td></tr><tr><td align="left">Case 24</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr><tr><td align="left">Case 25</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">IMC</td></tr><tr><td align="left">Case 26</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr></tbody></table>
###xml 873 934 867 928 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="58">IMC: intestinal metaplasia of cardia, BE: Barrett&#180;s Esophagus</p>
###xml 873 934 867 928 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="58">IMC: intestinal metaplasia of cardia, BE: Barrett&#180;s Esophagus</p></table-wrap-foot>
###xml 309 934 307 928 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="57">Haplotype analysis involving R213R, 13494 g&#8594;a and R72P polymorphisms of TP53</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Patient</th><th align="left">R213R</th><th align="left">13494 g&#8594;a</th><th align="left">R72P</th><th align="left">Histological type</th></tr></thead><tbody><tr><td align="left">Case 1</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr><tr><td align="left">Case 2</td><td align="left">AA</td><td align="left">AG</td><td align="left">RR</td><td align="left">BE</td></tr><tr><td align="left">Case 3</td><td align="left">AA</td><td align="left">AG</td><td align="left">RR</td><td align="left">BE</td></tr><tr><td align="left">Case 4</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr><tr><td align="left">Case 5</td><td align="left">AA</td><td align="left">AG</td><td align="left">PR</td><td align="left">IMC</td></tr><tr><td align="left">Case 6</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">ESOPHAGITIS</td></tr><tr><td align="left">Case 7</td><td align="left">AA</td><td align="left">AG</td><td align="left">RR</td><td align="left">ESOPHAGITIS</td></tr><tr><td align="left">Case 8</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr><tr><td align="left">Case 9</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">BE</td></tr><tr><td align="left">Case 10</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr><tr><td align="left">Case 11</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr><tr><td align="left">Case 12</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr><tr><td align="left">Case 13</td><td align="left">AA</td><td align="left">AG</td><td align="left">PR</td><td align="left">IMC</td></tr><tr><td align="left">Case 14</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">ESOPHAGITIS</td></tr><tr><td align="left">Case 15</td><td align="left">AA</td><td align="left">AG</td><td align="left">PR</td><td align="left">IMC</td></tr><tr><td align="left">Case 16</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr><tr><td align="left">Case 17</td><td align="left">AG</td><td align="left">AG</td><td align="left">PR</td><td align="left">BE</td></tr><tr><td align="left">Case 18</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">BE</td></tr><tr><td align="left">Case 19</td><td align="left">AG</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr><tr><td align="left">Case 20</td><td align="left">AA</td><td align="left">AG</td><td align="left">PP</td><td align="left">ESOPHAGITIS</td></tr><tr><td align="left">Case 21</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">ESOPHAGITIS</td></tr><tr><td align="left">Case 22</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">IMC</td></tr><tr><td align="left">Case 23</td><td align="left">AA</td><td align="left">GG</td><td align="left">RR</td><td align="left">BE</td></tr><tr><td align="left">Case 24</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr><tr><td align="left">Case 25</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">IMC</td></tr><tr><td align="left">Case 26</td><td align="left">AA</td><td align="left">GG</td><td align="left">PR</td><td align="left">BE</td></tr></tbody></table><table-wrap-foot><p textid="58">IMC: intestinal metaplasia of cardia, BE: Barrett&#180;s Esophagus</p></table-wrap-foot></table-wrap>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
###xml 204 212 <span type="species:ncbi:9606">patients</span>
The R213R and 13494 g-->a polymorphisms were jointly analyzed with the R27P polymorphism, previously reported by us using the same group of patients (Leistner-Segal et al. 2006). Analysis consisted of 26 patients for the three polymorphisms collectively. The genotypic patterns obtained are shown in Table 3. Table 3Haplotype analysis involving R213R, 13494 g-->a and R72P polymorphisms of TP53PatientR213R13494 g-->aR72PHistological typeCase 1AAGGPRBECase 2AAAGRRBECase 3AAAGRRBECase 4AAGGPRBECase 5AAAGPRIMCCase 6AAGGPRESOPHAGITISCase 7AAAGRRESOPHAGITISCase 8AAGGRRIMCCase 9AAGGRRBECase 10AAGGRRIMCCase 11AAGGPRBECase 12AAGGPRBECase 13AAAGPRIMCCase 14AAGGRRESOPHAGITISCase 15AAAGPRIMCCase 16AAGGRRIMCCase 17AGAGPRBECase 18AAGGRRBECase 19AGGGRRIMCCase 20AAAGPPESOPHAGITISCase 21AAGGRRESOPHAGITISCase 22AAGGRRIMCCase 23AAGGRRBECase 24AAGGPRBECase 25AAGGPRIMCCase 26AAGGPRBEIMC: intestinal metaplasia of cardia, BE: Barrett s Esophagus
###end p 56
###begin p 57
Haplotype analysis involving R213R, 13494 g-->a and R72P polymorphisms of TP53
###end p 57
###begin p 58
IMC: intestinal metaplasia of cardia, BE: Barrett s Esophagus
###end p 58
###begin p 59
The analysis demonstrates the conserved haplotype [AA, GG, RR] for the three polymorphisms. The alleles present in the previous haplotype are the most frequent in the general population, except for the R72P polymorphism that in the previous analysis carried out by our group showed predominance of the PR genotype.
###end p 59
###begin p 60
###xml 193 194 191 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 205 206 203 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 220 221 218 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
In the allele frequency analysis there were no significant difference between the three histological types (esophagitis, IMC and BE) for none of the polymorphisms, R213R, 13494 g-->a and R72P (P = 0.7600, P = 0.8438 and P = 0.8557, respectively).
###end p 60
###begin title 61
Discussion
###end title 61
###begin p 62
###xml 337 341 337 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">2003</xref>
The loss of cell cycle control and the progression to cancer in TP53 events in exons 5-8 are already well established. The functional significance and the frequency of polymorphisms in these regions still remain unknown. It is believed that they may contribute to a higher susceptibility (or resistance) to developing cancer (Vos et al. 2003).
###end p 62
###begin p 63
###xml 74 79 <span type="species:ncbi:9606">human</span>
A consistent association between these polymorphisms and several types of human neoplasias may serve as argument supporting such sites as susceptibility determiners (IARC). Furthermore, mutations in flanking regions of these exons are probably rare in spite of the biological significance they present.
###end p 63
###begin p 64
###xml 443 447 441 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">2000</xref>
###xml 468 472 466 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">2000</xref>
###xml 488 492 486 490 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">2000</xref>
###xml 509 513 507 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2005</xref>
The genes involved with tumor genesis are potential molecular markers associated to susceptibility to cancer. We thus investigated the relationship linking the R213R and 13494 g-->a polymorphisms of the p53 gene and the premalignant esophageal alterations (esophagitis, IMC and BE). Also, countless studies indicate an association between the R72P polymorphism at exon 4 of TP53 and the increased risk of developing neoplasias (Malcolm et al. 2000; Gottschlich et al. 2000; Nakano et al. 2000; Lacerda et al. 2005). Hence, we also carried out a joint analysis of the three polymorphisms described by means of a haplotype.
###end p 64
###begin p 65
###xml 587 591 585 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">2006</xref>
###xml 606 610 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">2004</xref>
###xml 151 158 <span type="species:ncbi:9606">patient</span>
In the present study the genotypic distribution of the R213R and 13494 g-->a polymorphisms are in agreement with the Hardy-Weinberg equilibrium in the patient group as well as in the control group. The genotypic analysis of both polymorphisms did not present a significantly different allele distribution compared to the control samples, which leads us to conclude that there is no correlation, at these stages, between such molecular findings and the histological types, although a strong ethnic variation with regard to the prevalence of these two polymorphisms (Leistner-Segal et al. 2006, Segal et al. 2004) is known to exist.
###end p 65
###begin p 66
###xml 54 58 54 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">1992</xref>
###xml 319 323 317 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">1995</xref>
###xml 551 555 549 553 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">1991</xref>
###xml 461 468 <span type="species:ncbi:9606">patient</span>
While analyzing the R213R polymorphism, Mazars et al. 1992 obtained results similar to ours for ovarian carcinoma and blood bank donor controls with prevalence of 3% and 2.6% for the polymorphic allele, respectively. In the analysis of the 13494 g-->a polymorphism for gastrointestinal and breast tumors, Peller et al. 1995 also found results similar to ours, with frequencies of the heterozygous AG genotype of 32% and 68% for homozygous GG genotypes, for the patient group. These results match the allele frequency described by Chumakov and Jenkins 1991, which was 31% for the AG genotype, and 69% for the GG genotype.
###end p 66
###begin p 67
###xml 420 424 420 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2004</xref>
###xml 560 564 560 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">2005</xref>
###xml 702 706 702 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">2004</xref>
It was anticipated that there would be a smaller proportion of the polymorphism in the exon 6 since the coding sequence is more conserved than the intronic region, mainly because the region in which this polymorphism is located carries great importance to the activity of the p53 protein. Eventual differences detected in several studies may be explained by ethnic differences between the groups analyzed (Brenna et al. 2004). Different genetic attributes may bestow protection against or risk for developing cancer in populations of diverse ancestries (Rocha 2005). However, other reasons such as sample size, DNA source, and techniques employed should also be taken into consideration (Brenna et al. 2004).
###end p 67
###begin p 68
###xml 168 169 168 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 139 147 <span type="species:ncbi:9606">patients</span>
###xml 252 260 <span type="species:ncbi:9606">patients</span>
###xml 311 318 <span type="species:ncbi:9606">patient</span>
In the combined analysis with the R72P polymorphism previously studied by our group, a similar frequency was observed in both controls and patients. According to Table 3, the most frequent haplotype was [AA, GG, RR] which occurred in 34.6% of analyzed patients. Since the most frequent haplotype is the same in patient and control groups, we may think again that the absence of association between these three polymorphisms and the esophageal alterations stems from the fact that molecular alterations can only be identified in more advanced stages of the normal tissue-metaplasia-adenocarcinoma progression.
###end p 68
###begin p 69
###xml 243 247 243 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">2002</xref>
###xml 497 501 497 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">1996</xref>
###xml 515 519 515 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">2003</xref>
The LOH findings are in agreement with the occurrence of genomic instability seen in various types of cancer, and serve as encouragement to the understanding of DNA repair processes in replication and recombination events (Thiagalingam et al. 2002). All tissue samples presented the wild allele indicating that cells carrying the analyzed polymorphisms were heterozygotic or that many normal cells (lacking polymorphism) were present in the tissue from which DNA was extracted (Campomenosi et al. 1996, Doak et al. 2003). This fact may have minimized the LOH findings in our study.
###end p 69
###begin p 70
###xml 128 132 128 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">2000</xref>
###xml 306 310 306 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">1999</xref>
###xml 324 328 324 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">2001</xref>
###xml 345 349 345 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">1994</xref>
The allelic loss associated to esophageal carcinogenesis was found by Kawaguchi for the codon 72 polymorphism (Kawaguchi et al. 2000). Abnormalities involving the TP53 are common with esophageal adenocarcinoma and have been detected in pre-malignant tissues surrounding the esophageal cancer (Prevo et al. 1999; Reid et al. 2001). Neshat et al. 1994 reported molecular and genomic alterations identifying LOH in 94% of Barrett cancers and 88% of mutations in the TP53. Allelic loss of 17p has been detected in initial stages of high-degree metaplasia and dysplasia, leading to aneuploidy and suggesting that inactivation of the TP53 is a first step in carcinogenesis. Both cases of LOH located in the intron 6 reinforce the data in literature for these events being found in altered tissues and also highlight the presence of alterations within the non-coding region. Such alterations may alter the phenotype of the protein being coded and are of considerable value in understanding the genic expression.
###end p 70
###begin p 71
###xml 32 36 32 36 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">1996</xref>
###xml 335 339 335 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">2005</xref>
According to Campomenosi et al. 1996 the association of the molecular findings with the histological type occurs upon development of the BE since the type I metaplasia (common in BE) would be more responsive to damage caused by GERD and therefore more prone to developing aneuploidies than the tissues analyzed in our study (Li et al. 2005). Without doubt, this could provide an explanation to the fact that our results do not differ from those in the control population, since the tissues assayed were in early stages of BE development.
###end p 71
###begin p 72
###xml 308 312 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2005</xref>
###xml 206 214 <span type="species:ncbi:9606">patients</span>
There is increasing evidence that new mechanisms including mutation in splicing sites, introns and promoter regions are involved in the genic expression. Identification of these alterations may help select patients with a higher risk of developing cancer, allowing optimization of treatments (Lacerda et al. 2005).
###end p 72
###begin p 73
###xml 150 158 <span type="species:ncbi:9606">patients</span>
Considering our data regarding the incidence of alleles, genotypes and haplotypes of the R213R, 13494 g-->a and R72P polymorphisms of the p53 gene in patients and controls, we can suggest that these three sites do not represent genetic susceptibility determiners to esophagitis, intestinal metaplasia of the cardia and BE. Additional studies are required in order to investigate these three polymorphisms in advanced stages of carcinogenesis.
###end p 73
###begin title 74
Acknowledgements
###end title 74
###begin p 75
This work received editorial support from the Research and Postgraduate Group of Hospital de Clinicas of Porto Alegre (RS, Brazil) and financial support from the Research Support Foundation of Rio Grande do Sul (FAPERGS), Coordination for the Improvement of Higher Education Personnel (CAPES) and the Research Support Fund/Hospital de Clinicas of Porto Alegre (FIPE-HCPA).
###end p 75
###begin title 76
References
###end title 76
###begin article-title 77
p53 genes polymorphism in the Turkish population
###end article-title 77
###begin article-title 78
Barrett's esophagus: an overview of the molecular biology
###end article-title 78
###begin article-title 79
Molecular analysis of the TP53 gene in Barrett's Adenocarcinoma
###end article-title 79
###begin article-title 80
A more accurate detection of codon 72 polymorphism and LOH of the TP53 gene
###end article-title 80
###begin article-title 81
Barrett s adenocarcinoma arises within a single aneuploid population
###end article-title 81
###begin article-title 82
Prognostica value of p53 codon 72 polymorphism in invasive cervical cancer in Brazil
###end article-title 82
###begin article-title 83
p53 is frequently mutated in Barrett s metaplasia of intestinal type
###end article-title 83
###begin article-title 84
###xml 31 36 <span type="species:ncbi:9606">human</span>
BstNI/NciI polymorphism of the human p53 gene (TP53)
###end article-title 84
###begin article-title 85
Characterisation of p53 status at the gene, chromosomal and protein levels in oesophageal adenocarcinoma
###end article-title 85
###begin article-title 86
The tumor suppressor p53
###end article-title 86
###begin article-title 87
Genetics and prevention of oesophageal adenocarcinoma
###end article-title 87
###begin article-title 88
p53 analysis of laryngeal cancer in exon 4 to 9
###end article-title 88
###begin article-title 89
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Allelic loss in esophageal squamous cell carcinoma patients with and without family history of upper gastrointestinaltract cancer
###end article-title 89
###begin article-title 90
###xml 20 40 <span type="species:ncbi:10566">human papillomavirus</span>
p53 Polymorphism in human papillomavirus-associated esophageal cancer
###end article-title 90
###begin article-title 91
###xml 52 57 <span type="species:ncbi:9606">woman</span>
An intronic variant in the TP53 gene in a Brazilian woman with breast cancer
###end article-title 91
###begin article-title 92
###xml 43 51 <span type="species:ncbi:9606">patients</span>
The p53 gene R72P polymorphism analysis in patients with Barrett s Esophagus compared to normal controls
###end article-title 92
###begin article-title 93
###xml 35 40 <span type="species:ncbi:9606">human</span>
Mutations of p53 gene exons 4-8 in human esophageal cancer
###end article-title 93
###begin article-title 94
Polymorphism at codon 72 of p53 is not associated with cervical cancer risk
###end article-title 94
###begin article-title 95
Necleotide sequence polymorphirsm in a hotspot mutation region of the p53 gene
###end article-title 95
###begin article-title 96
###xml 55 60 <span type="species:ncbi:9606">human</span>
A simple salting out procedure for extracting DNA from human nucleated cells
###end article-title 96
###begin article-title 97
Poor clinical significance of p53 gene polymorphism in acute myeloid leukemia
###end article-title 97
###begin article-title 98
###xml 32 37 <span type="species:ncbi:9606">human</span>
Barrett s esophagus: a model of human neoplastic progression
###end article-title 98
###begin article-title 99
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Characterization of a frequent polymorphism in the coding sequence of the TP53 gene in colonic cancer patients and a control population
###end article-title 99
###begin article-title 100
###xml 40 45 <span type="species:ncbi:9606">human</span>
A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility
###end article-title 100
###begin article-title 101
P53-mutant clones and field effects in Barrett s Esophagus
###end article-title 101
###begin article-title 102
Progression to cancer in Barrett s esophagus is associated with genomis instability
###end article-title 102
###begin article-title 103
###xml 108 115 <span type="species:ncbi:9606">patient</span>
Predictors of progression in Barrett s Esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression
###end article-title 103
###begin article-title 104
Flow-cytometry and histological progression to malignancy in Barrett s esophagus: prospective endoscipic surveillance of a cohort
###end article-title 104
###begin article-title 105
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Barrett s esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma
###end article-title 105
###begin article-title 106
###xml 48 56 <span type="species:ncbi:9606">patients</span>
p53 overexpression and p53 mutation analysis in patients with intestinal metaplasia of the cardia and Barrett s Esophagus
###end article-title 106
###begin article-title 107
Gastroesophageal reflux, Barrett s Esophagus and esophageal cancer
###end article-title 107
###begin article-title 108
P53 codon 72 polymorphism and association with bladder cancer
###end article-title 108
###begin article-title 109
###xml 70 75 <span type="species:ncbi:9606">human</span>
The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer
###end article-title 109
###begin article-title 110
Loss of heterozygosity as a predictor to map tumor supressor genes in cancer: molecular basis of its occurrence
###end article-title 110
###begin article-title 111
Polymorphisms and mutations found in the regions flanking exons 5 to 8 of the TP53 gene in a population at high risk for esophageal cancer in South Africa
###end article-title 111
###begin title 112
Abbreviations
###end title 112
###begin p 113
Barrett's esophagus
###end p 113
###begin p 114
intestinal metaplasia of the cardia
###end p 114
###begin p 115
p53 gene
###end p 115
###begin p 116
loss of heterozygosity
###end p 116
###begin p 117
gastroesophageal reflux disease
###end p 117

